^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    α1 adrenergic receptor antagonist

    Related drugs:
    3d
    Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort (clinicaltrials.gov)
    P2, N=36, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P1, N=15, Recruiting, University of Iowa | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy (clinicaltrials.gov)
    P4, N=1844, Not yet recruiting, Peking University First Hospital
    New P4 trial
    10d
    Tamsulosin and the Risk of Serious Adverse Events (clinicaltrials.gov)
    P=N/A, N=14000, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
    New trial • Adverse events • Serious adverse event
    17d
    Retrograde Intrarenal Surgery Combined with Tamsulosin Hydrochloride for Renal Calculi ≤2 cm: Single-Center Study. (PubMed, Arch Esp Urol)
    RIRS combined with tamsulosin demonstrates remarkable short-term clinical efficacy, stone clearance and renal function protection in patients with renal calculi ≤2 cm, showing promising clinical application.
    Retrospective data • Journal
    |
    IL6 (Interleukin 6) • B2M (Beta-2-microglobulin) • CRP (C-reactive protein)
    1m
    A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Pfizer
    New P1 trial
    2ms
    TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Iowa
    New P1 trial
    2ms
    Induction of apoptosis and growth inhibition by silodosin and abiraterone acetate in PC-3 human prostate cancer cells. (PubMed, Investig Clin Urol)
    Silodosin exhibits potent effects in reducing cell viability and promoting apoptosis in androgen-insensitive prostate cancer cells, comparable to AA. When combined, both agents demonstrate synergistic effects with reduced dosing requirements. These findings support further investigation of silodosin as a potential therapeutic in mCRPC.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    abiraterone acetate • silodosin
    2ms
    A Randomized Controlled Trial on the Efficacy and Safety of Urinary Stone Relief Pills Combined with Tamsulosin in the Treatment of Upper Urinary Tract Stones (Including Postoperative Residual Stones) (ChiCTR2500110177)
    P4, N=144, Not yet recruiting, Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology; Tongji Hospital, Affiliated to Tongji Medical
    New P4 trial
    2ms
    Clinical Drug Study on the Efficacy and Safety of Niaoqingshu Granules in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (ChiCTR2500108889)
    P4, N=80, Completed, The First Affiliated Hospital of Sun Yat sen University; The First Affiliated Hospital of Sun Yat sen University
    New P4 trial
    2ms
    Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Pharmazz, Inc. | N=60 --> 80 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    3ms
    EJS ACT-PD: Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (clinicaltrials.gov)
    P3, N=1200, Recruiting, University College, London
    New P3 trial